Endotypic Traits and Obstructive Sleep Apnea Surgery
ConditionObstructive Sleep Apnea
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age21+
SponsorUniversity of California, Los Angeles
About this trial
This study will examine factors associated with outcomes after soft palate surgery and medications (acetazolamide, eszopiclone) that may treat other potential causes of obstructive sleep apnea (loop gain, arousal threshold).
Eligibility criteria
Qualifiers
age ≥21 years;
moderate to severe OSA (obstructive AHI ≥ 15 events/hour);
central/mixed apnea index <5 events/hour;
intolerance of positive airway pressure (defined as use < 2 hours/night at least 5 nights/week);
Disqualifiers
history of allergic reaction to either of the study drugs;
subjects with prior serious allergic reaction (such as Stevens-Johnson syndrome) to sulfonamides;
subjects with a history of hypersensitivity to either of the two study drugs;
subjects who are on high-dose aspirin therapy due to risk of severe metabolic acidosis;
Trial design
Treatments tested in this trial
- Acetazolamide 500 MG QHS
- Eszopiclone 3 mg QHS
Treatment groups
150 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of California, Los Angeles
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Source ClinicalTrials.gov